Development of 3D vascularized model of Blood Brain Barrier and its application to Alzheimer disease research

NIH RePORTER · NIH · R21 · $200,500 · view on reporter.nih.gov ↗

Abstract

SUMMARY As the population grows older, the demand for improved methods to study cerebrovascular diseases has rapidly increased. At the same time, there has been burgeoning interest in reproducing physiological properties of blood- brain-barrier (BBB) in vitro that can be helpful in both basic and clinical studies. A need therefore exists for standardized models as tools to help scientists better understand the physiological and pathological mechanisms involved in cerebrovascular diseases, including Alzheimer’s disease (AD). The proposed studies are aimed at developing a versatile BBB model that recapitulates BBB microvascular networks (µVNs) in a three dimensional (3D) microfluidic platform, and apply this model to AD pathogenesis research. Building on our extensive set of preliminary and related data, we propose to recreate 3D AD-BBB µVNs within extracellular matrix (ECM) scaffolds that enable intercellular signaling and exposure to biochemical gradients in a well-defined microenvironment. AD is a progressive neurodegenerative disease which is characterized by deterioration of cognitive function and deposition of β-amyloid (Aβ) peptides. We previously reported that human neural progenitor cells overexpressing Familial AD (FAD) mutations in the amyloid-β precursor protein (APP) and presenilin 1 (PSEN1) genes grown in a 3D culture system successfully recapitulate AD pathologies (3D AD culture model). However, this model lacks BBB components, which are critical to neurological function and AD pathogenesis. We will develop 3D- differentiated AD cells in a 3D microfluidic platform in the presence of the BBB µVNs (3D AD-BBB µVN model). We will investigate how the BBB is disrupted in AD and whether optimizing the BBB can ameliorate AD progression. Our 3D AD-BBB µVN model will be useful for both BBB-related disease pathogenic cascades, such as AD, and drug discovery in a human brain-like environment.

Key facts

NIH application ID
10016386
Project number
5R21NS105027-02
Recipient
MASSACHUSETTS INSTITUTE OF TECHNOLOGY
Principal Investigator
ROGER D KAMM
Activity code
R21
Funding institute
NIH
Fiscal year
2020
Award amount
$200,500
Award type
5
Project period
2019-09-15 → 2021-08-31